Theralase Technologies Inc.
OTC Bulletin Board : TLTFF

Theralase Technologies Inc.

November 28, 2006 08:00 ET

Theralase Technologies Inc. Announces Operating Profits for the Third Quarter of Fiscal 2006

TORONTO, ONTARIO--(CCNMatthews - Nov. 27, 2006) - Theralase Technologies Inc. (TSX VENTURE:TLT)(OTCBB:TLTFF) announced unaudited financial results for the quarter ended September 30, 2006. Positive earnings have been maintained from fiscal 2004 through the first 3 quarters of 2006.

3 month period ending 9 month period ending
Highlights September 30, September 30, September 30, September 30,
2006 2005 2006 2005

Revenue $326,793 $300,273 $1,042,471 $782,157
Net Income $ 4,839 ($ 4,017) $134,973 $28,469

Year to date revenues totalled $1,042,471, a 33% increase over the $782,157 in revenues reported for the same period last year. Reportable operating earnings per share were, positive at less than one cent per share.

Highlights for the period under review include:

- Theralase introduces new auriculotherapy (ear acupuncture) probe for smoking cessation and weight loss.

- Completion of the research and development phase of the biofeedback project.

- Commencement of the photodynamic compound (PDC) therapy project.

- Theralase announces the appointment of David M. Groves, B.A. as President of Theralase's World Trade Division.

- Theralase announces the appointment of Mr. Anselm Viswasam, P. Eng., MBA as Production Manager and Research and Development Manager.

For detailed financial statements for the quarter, including Management Discussion and Analysis, please refer to our corporate website at or regulatory website at

Theralase Technologies Inc. designs, develops, manufactures and sells leading edge, proprietary, high powered, super-pulsed therapeutic laser equipment employed in a wide range of biostimulative medical therapy applications. The Theralase technology platform targets several diverse healthcare sectors -- firstly, for non-invasive pain management, control and therapy, including a wide range of neural-musculo-skeletal conditions, arthritic and rheumatologic disorders -- secondly, to bio-stimulate and accelerate wound care and healing, including: bone fracture regeneration and osteoarthritic conditions -- and thirdly, combining proprietary metallic complexes with photo-dynamic lasers to attack specifically-targeted cancerous growths.

For a complete profile of Theralase Technologies Inc. and its products visit

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

Contact Information